Detrol: Regain Control Over Overactive Bladder Symptoms
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.38 | $41.30 (0%) | 🛒 Add to cart |
| 60 | $1.16 | $82.59 $69.50 (16%) | 🛒 Add to cart |
| 90 | $1.09 | $123.89 $97.70 (21%) | 🛒 Add to cart |
| 120 | $1.06 | $165.19 $126.91 (23%) | 🛒 Add to cart |
| 180 | $1.02 | $247.78 $183.32 (26%) | 🛒 Add to cart |
| 270 | $1.00 | $371.67 $268.93 (28%) | 🛒 Add to cart |
| 360 | $0.99
Best per pill | $495.56 $355.56 (28%) | 🛒 Add to cart |
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.22 | $66.48 (0%) | 🛒 Add to cart |
| 60 | $1.86 | $132.96 $111.80 (16%) | 🛒 Add to cart |
| 90 | $1.76 | $199.43 $158.14 (21%) | 🛒 Add to cart |
| 120 | $1.70 | $265.91 $203.46 (23%) | 🛒 Add to cart |
| 180 | $1.63 | $398.87 $294.12 (26%) | 🛒 Add to cart |
| 270 | $1.59 | $598.30 $430.09 (28%) | 🛒 Add to cart |
| 360 | $1.57
Best per pill | $797.74 $566.07 (29%) | 🛒 Add to cart |
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.69 | $110.80 (0%) | 🛒 Add to cart |
| 60 | $2.87 | $221.59 $172.24 (22%) | 🛒 Add to cart |
| 90 | $2.59 | $332.39 $232.67 (30%) | 🛒 Add to cart |
| 120 | $2.44 | $443.19 $293.11 (34%) | 🛒 Add to cart |
| 180 | $2.30 | $664.78 $413.98 (38%) | 🛒 Add to cart |
| 270 | $2.21
Best per pill | $997.17 $597.30 (40%) | 🛒 Add to cart |
Synonyms | |||
Detrol (tolterodine tartrate) is a prescription medication specifically formulated for the treatment of overactive bladder (OAB). It belongs to a class of drugs known as antimuscarinics or anticholinergics, which work by relaxing the bladder muscle. This action helps to reduce symptoms of urinary urgency, frequency, and incontinence, allowing patients to experience fewer interruptions to their daily lives and improved quality of sleep. Approved by the FDA, Detrol is a well-established option in urological and gynecological practice for managing this common and often distressing condition.
Features
- Active ingredient: Tolterodine tartrate
- Available in immediate-release tablets (1 mg and 2 mg) and extended-release capsules (2 mg and 4 mg)
- Selective muscarinic receptor antagonist with affinity for bladder tissue
- Demonstrated efficacy in reducing urge incontinence episodes and micturition frequency
- Convenient twice-daily (immediate-release) or once-daily (extended-release) dosing
- Bioavailability of approximately 77% for the immediate-release formulation
- Metabolized primarily by the cytochrome P450 2D6 (CYP2D6) enzyme system
Benefits
- Significantly reduces the number of urge incontinence episodes per week
- Decreases urinary frequency, allowing for longer intervals between bathroom visits
- Diminishes the sudden, strong need to urinate (urgency)
- Improves overall quality of life by reducing sleep disruptions due to nocturia
- Helps restore confidence in social and professional settings by minimizing accidents
- Provides flexible dosing options to suit individual patient needs and lifestyles
Common use
Detrol is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is commonly prescribed for adults experiencing these symptoms, which may be associated with conditions such as idiopathic detrusor overactivity or neurogenic bladder disorders. The medication is often part of a comprehensive management plan that may include behavioral modifications, pelvic floor exercises, and fluid management strategies.
Dosage and direction
The recommended dosage for Detrol immediate-release tablets is 2 mg twice daily. For patients with certain factors (such as significantly reduced hepatic function or those taking potent CYP3A4 inhibitors), the dose may be reduced to 1 mg twice daily. Detrol LA extended-release capsules are typically prescribed as 4 mg once daily, which may be reduced to 2 mg daily if needed. The medication can be taken with or without food, but consistency in administration with respect to meals is advised. Tablets should be swallowed whole with water; the capsules should not be chewed, divided, or crushed.
Precautions
Patients should be advised that Detrol may cause blurred vision, dizziness, or drowsiness, which could impair their ability to drive or operate machinery. Caution is recommended when engaging in activities requiring alertness until the patient’s response to the drug is known. Elderly patients may be more sensitive to the effects of Detrol, particularly regarding cognitive effects such as confusion or memory impairment. Those with clinically significant bladder outflow obstruction, gastrointestinal obstructive disorders, or renal impairment should use Detrol with caution and under close medical supervision.
Contraindications
Detrol is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. It should not be used by patients who have demonstrated hypersensitivity to tolterodine tartrate or any components of the formulation. Additionally, Detrol is contraindicated in patients with myasthenia gravis or severe ulcerative colitis, and in those with toxic megacolon complicating ulcerative colitis.
Possible side effect
Common side effects (≥5% of patients) include dry mouth, headache, constipation, abdominal pain, dyspepsia, xerophthalmia (dry eyes), dizziness, and somnolence. Less frequently reported adverse reactions include urinary retention, confusion (particularly in elderly patients), tachycardia, palpitations, hallucinations, and allergic reactions including rash and angioedema. Patients should be monitored for signs of anticholinergic effects, which may include blurred vision, increased intraocular pressure, and reduced gastrointestinal motility.
Drug interaction
Detrol may interact with other drugs that possess anticholinergic properties, potentially increasing the frequency and/or severity of side effects. Potent inhibitors of CYP3A4 (such as ketoconazole, itraconazole, clarithromycin) may increase tolterodine plasma concentrations, requiring dosage adjustment. Fluoxetine (a CYP2D6 inhibitor) may also increase tolterodine levels. Concurrent use with other drugs that prolong the QT interval should be approached with caution. Detrol may reduce the efficacy of metoclopramide and other prokinetic agents.
Missed dose
If a dose of Detrol is missed, patients should take it as soon as they remember, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one, as this may increase the risk of adverse effects.
Overdose
In case of overdose, patients may experience severe central anticholinergic effects including hallucinations, severe dizziness, seizures, respiratory depression, and cardiac arrhythmias. Management should include gastric lavage and administration of activated charcoal if presented early. Symptomatic and supportive treatment is essential, with particular attention to maintaining airway patency and cardiovascular stability. Physostigmine may be considered in severe cases, but should be administered with caution due to the risk of precipitating seizures or bradycardia.
Storage
Detrol should be stored at room temperature (20-25°C or 68-77°F), in a tightly closed container, and protected from light and moisture. Keep out of reach of children and pets. Do not store in bathroom cabinets where humidity levels may fluctuate. Properly discard any unused medication after the expiration date or when no longer needed, following appropriate medication disposal guidelines.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Detrol is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Patients should not initiate, discontinue, or change their dosage without consulting their physician. Individual results may vary, and the full prescribing information should be consulted before use.
Reviews
Clinical studies have demonstrated that Detrol significantly improves overactive bladder symptoms compared to placebo. In randomized controlled trials, patients taking Detrol experienced approximately 50% reduction in incontinence episodes and significant improvement in urinary frequency parameters. Many patients report improved quality of life measures, particularly regarding social functioning and sleep quality. Some users note dry mouth as the most bothersome side effect, though this often diminishes with continued use. Healthcare providers generally consider Detrol to be a well-tolerated and effective option for OAB management, particularly appreciating the availability of both immediate and extended-release formulations to tailor therapy to individual patient needs.